Lv5
1098 积分 2023-05-17 加入
SPIROMICS HF: Rationale, Design, and Reproducibility of Measures
2个月前
已完结
The addition of vericiguat to sacubitril/valsartan improved the composite endpoint. Add a finishing touch on heart failure medical therapy by vericiguat as secret ingredient
2个月前
已关闭
Treatment With Myosin Inhibitor in a Patient With Symptomatic Hypertrophic Cardiomyopathy With Isolated Right Ventricular Obstruction
3个月前
已完结
Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy
3个月前
已完结
SPOP Is a Key Trigger of Pathological Cardiac Hypertrophy and Heart Failure
3个月前
已完结
Myosin Mayhem: Losing (or Gaining) Its Chill in Hypertrophic Cardiomyopathy
3个月前
已完结
High Sensitivity Troponin for Contemporary Risk Stratification in Wild-Type ATTR Amyloidosis
6个月前
已完结
Letter by Zhang and Zeng Regarding Article, “Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry”
8个月前
已完结
Response by Maurizi et al to Letter Regarding Article, “Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry”
8个月前
已完结
皖公网安备34019202002308
